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ABSTRACT
Introduction: Intanza® 9 μg (Sanofi Pasteur SA, 
Lyon, France), a split virion trivalent influenza 
vaccine delivered by intradermal injection 
with a microinjection system, became available 
as a  vaccination for adults aged 18 to 
59 years old, as of the 2010 southern 
hemisphere influenza season. Methods: This 
study was designed to assess the acceptability 
of intradermal vaccination with Intanza 9 μg in 
routine clinical practice by adult vaccinees and 
their prescribers. Prescribers and healthy adults 
18 to 59 years old in Australia and Argentina 
who had elected to be vaccinated with Intanza 
9 μg during the 2010 southern hemisphere 
influenza season were recruited to complete 
surveys about their opinions of influenza 
vaccination and acceptance of the intradermal 
vaccination. Results: 1402 vaccinees and 
30 prescribers in Australia, and 264 vaccinees 
and 16 prescribers in Argentina responded to 
surveys. In both countries, 98% of vaccinees 
were satisfied or very satisfied with Intanza 9 μg. 
The main reasons for satisfaction were that the 
injection was considered minimally painful and 
that the vaccination was quickly administered. 
Most (95%) vaccinees reported that they would 
prefer to receive the same vaccination next 
year. Furthermore, 85% of prescribers were 
satisfied or very satisfied with the intradermal 
vaccine. Conclusion: Intradermal vaccination 
for seasonal influenza using Intanza 9 μg is well 
accepted both by adult vaccinees and prescribers. 
By providing an additional, well-accepted 
method, Intanza 9 μg might help increase 
seasonal influenza vaccination rates in adults.
Keywords: acceptability; influenza; intradermal; 
seasonal; trivalent inactivated; vaccine 
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INTRODUCTION
Seasonal influenza is a disease with a substantial 
clinical and economic burden,1 and the death 
rate is increased 50- to 100-fold in people with 
underlying illnesses.2 Vaccination is the most 
effective means of preventing seasonal influenza 
infections.1 In adults, coverage rates remain 
low. For example, a survey of 11 European 
countries found that vaccine coverage during 
the 2007/2008 influenza season ranged from 
9.5% to 28.7% in adults and 11.1% to 56.0% in 
chronically ill persons.3
Until now, trivalent inactivated seasonal 
influenza vaccines have been administered 
primarily by intramuscular (IM) injection. 
Vaccination by the intradermal (ID) route 
using a microinjection system has been 
proposed as a way of improving influenza 
vaccine uptake because it uses a much smaller 
needle than the IM needle and because it 
allows rapid and safe vaccination.4 Intanza®, 
the first microneedle trivalent inactivated 
influenza vaccine, is administered using the 
BD Soluvia™ microinjection system (Becton, 
Dickinson and Company, Franklin Lakes, NJ, 
USA), which consists of a 0.5-mL glass syringe 
fitted with a 30-gauge, short-bevel microneedle 
that protrudes 1.5 mm from a depth-limiting 
tip.5 Clinical studies have shown that Intanza 
9 μg is non-inferior, and has a similar safety 
profile, to Vaxigrip® 15 μg in adults 18 to 
59 years of age.6 Also, in a phase 3 clinical study 
conducted in adults aged ≥60 years, Intanza 
15 μg was superior and had a similar safety 
profile to Vaxigrip 15 μg.7 Intanza was approved 
first in Europe in 2009 by the European 
Medicines Agency for the prevention of 
influenza in both working-age adults (18 to 
59 years; 9 μg hemagglutinin per strain) and 
older adults (≥60 years; 15 μg hemagglutinin 
per strain).5,8 Intanza was also approved in 
Australia in 2010 and was launched in adults for 
the 2010 southern hemisphere influenza season. 
In Argentina, Intanza 9 μg was approved in late 
2009 under the name Istivac ID® 9 μg.
The performance and reliability of ID 
vaccination with Intanza was confirmed in a 
total of 9110 subjects enrolled in randomized 
clinical trials in six European countries, New 
Zealand, and Australia,5 but its acceptance in 
routine clinical practice has not been directly 
evaluated. Here, we assessed the acceptability 
of ID influenza vaccination with Intanza 9 μg 
under routine conditions of use during the 2010 
southern hemisphere influenza season. The 
study was performed in Argentina and Australia, 
the two countries in which Intanza 9 μg was first 
marketed. In the Argentinean study, we also 
collected opinions of vaccinees by telephone 
survey 7 to 10 days after vaccination.
MATERIALS AND METHODS
Study Design and Participants
This was an uncontrolled survey of the 
acceptance of Intanza 9 μg in routine clinical 
practice by adult subjects and healthcare 
practitioners. The survey was carried out 
in Argentina and Australia during the 2010 
southern hemisphere influenza season 
following entry of Intanza 9 μg into the market. 
Healthcare professionals in general practice and 
occupational health clinics across Victoria, New 
South Wales, and Queensland, Australia, and in 
vaccination clinics in the greater Buenos Aires 
area, Argentina, asked adults aged 18 to 59 years 
old whether they would like to be vaccinated 
with Intanza 9 μg in place of an IM influenza 
vaccine. Other than discussing the features of 
Intanza 9 μg, healthcare professionals provided 
no additional information or reading materials. 
Those who elected to be vaccinated with Intanza®
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9 μg and were willing to complete surveys were 
sequentially enrolled in the survey. The survey 
was carried out between April 28 and June 23, 
2010 in Australia and between July 12 and 
August 31, 2010 in Argentina. Each vaccinee was 
required to provide written informed consent 
prior to receiving the vaccine and had to be 
vaccinated in order to be included in the survey. 
Exclusion criteria included hypersensitivity to 
the active substances or any of the excipients. 
Immunization was postponed in vaccinees with 
febrile illness or acute infection.
Treatment and Assessments
Immediately after being vaccinated with Intanza 
9 μg, vaccinees completed a self-administered 
questionnaire in English (Australia) or Spanish 
(Argentina). This questionnaire collected 
demographic information and asked the subjects 
about their perception of risk for contracting 
influenza, their influenza vaccination history, 
satisfaction with the ID vaccination, and their 
vaccine preference for the next year. Seven to 10 
days after vaccination, vaccinees participating 
in the Argentinean survey were contacted by 
telephone and asked again about their vaccine 
preference for the next year. Up to three 
attempts were made to contact vaccinees. At the 
end of the influenza season and after all patients 
had been vaccinated, prescribers completed 
a questionnaire that asked them about their 
satisfaction with Intanza 9 μg.
Statistical Analysis
All analyses were performed using SAS version 
9.1 (SAS Institute, Cary, NC, USA). Categorical 
variables were described by the percentage 
of each response choice, with missing data 
excluded in the calculation of percentage. 
RESULTS
Intanza 9 μg Vaccinee Responses
Demographics
The survey in Australia included 1402 
vaccinees, and the survey in Argentina 
included 264 vaccinees. Both studies included 
approximately equal numbers of men and 
women (Table 1). Most (70.0%) of the vaccinees 
Australia Argentina Overall
Parameter n % n % n %
Answering self-administered 
questionnaire
1402 100 264 100 1666 100
Answering telephone survey - - 208 78.9 - -
Sex N=1401 N=258 N=1659
Male 692 49.4 126 48.8 818 49.3
Female 709 50.6 132 51.2 841 50.7
Age N=1399 N=263 N=1662
18-49 years 939 67.1 225 85.6 1164 70.0
50-59 years 412 29.4 38 14.4 450 27.1
60-74 years 48 3.4 0 0.0 48 2.9
Demographic results were from a self-administered questionnaire. Percentages were calculated as 100 × (number in each 
category [n] ÷ the total number of responses available for each question [N]).
Table 1. Vaccinee demographics.
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were 18 to 49 years old. The remainder were 
mostly 50 to 59 years old, although a few 
vaccinees in the Australian survey (n=48; 
3.4% in Australia; 2.9% overall) were 60 to 
74 years old, which constituted an off-label use 
of the vaccine, although all respondents were 
included in the analysis. 
Vaccinees’ Feeling of Risk for Contracting 
Influenza
Most vaccinees (63.6% in Australia, 56.3% 
in Argentina; 62.5% overall) felt at risk for 
contracting seasonal influenza (Table 2). For 
those feeling at risk in Australia, the most 
common reason was “I come into contact with 
many people in my daily life” (71.3%), but in 
Argentina, this was cited less often (31.8%). 
Also, “I have a chronic illness” was a common 
reason for feeling at risk in Argentina (23.6%) 
but not in Australia (4.3%). 
Less than half of vaccinees (36.4% in 
Australia, 43.7% in Argentina; 37.5% overall) did 
not feel at risk for contracting seasonal influenza. 
The most common reasons for not feeling at risk 
in either Argentina or Australia were “I ensure a 
healthy lifestyle,” and “I have no chronic illness 
to consider myself at risk for flu.” “I rely on the 
strength of my natural defenses” was one of the 
most common reasons for not feeling at risk 
in Australia (26.8%) but was less important in 
Argentina (13.9%).
Frequency of Vaccination
More than half (55.1%) of vaccinees in Australia 
reported being vaccinated against seasonal 
influenza every year, while approximately 
one-third (29.9%) said that it was their first time 
(Table 2). In Argentina, in contrast, the majority 
(70.5%) reported that it was their first time to 
be vaccinated for seasonal influenza, and fewer 
than one in five (18.6%) reported that they were 
vaccinated every year. 
Main Reasons for Being Vaccinated
The main reasons for being vaccinated during 
this study differed between the two countries 
(Table 2). In Australia, the most common reason 
for being vaccinated was “my own belief of the 
importance of flu vaccination” against seasonal 
influenza (43.5%), and only 15.1% of vaccinees 
mentioned “physician/GP advice” as the main 
reason for being vaccinated. In Argentina, the 
most common reason for being vaccinated was 
“physician/GP advice” (76.1%), and “my own 
belief of the importance of flu vaccination” 
against seasonal influenza was cited by only 
9.5% of vaccinees.
Main Reasons for Missing Previous 
Vaccinations
For vaccinees who reported missing previous 
influenza vaccinations, the main reason reported 
was “I didn’t feel I was at risk of getting flu” 
(69.5% in Argentina and 43.3% in Australia) 
(Table 2). In Australia, another major reason 
(32.4%) for missing previous vaccinations was 
“I was not encouraged to be vaccinated.” “I have 
a fear of injections/needle size” and “I was afraid 
of side effects/contracting flu from the vaccine” 
were infrequently reported as reasons for not 
being vaccinated in both Australia (9.7% and 
13.7%, respectively) and Argentina (1.0% and 
4.1%, respectively).
Vaccinee Satisfaction with Intanza 9 μg 
Vaccinees’ satisfaction with Intanza 9 μg was 
high and quite similar in the two countries. 
When asked immediately after the vaccination, 
98% of vaccinees in both countries reported 
being “very satisfied” or “satisfied” with the 
immunization, and only 0.4% to 0.5% reported 
being “unsatisfied” (Figure 1A). The two main 
reasons for satisfaction in both countries were 
“the injection was minimally painful” and “the 
administration process was quick” (Figure 1B). 
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Table 2. Vaccinees’ opinions and history of vaccination for seasonal influenza.
Australia Argentina Overall
Questions/answers n % n % n %
Do you feel at risk of getting flu? N=1400 N=263 N=1663
Yes 891 63.6 148 56.3 1039 62.5
No 509 36.4 115 43.7 624 37.5
Reason for feeling at risk N=888 N=148 N=1036
I come into contact with many people in my daily life 633 71.3 47 31.8 680 65.6
I have previously experienced flu 157 17.7 10 6.8 167 16.1
I am at risk because of my older age 58 6.5 2 1.4 60 5.8
I have a chronic illness 38 4.3 35 23.6 73 7.0
Other 2 0.2 54 36.5 56 5.4
Reason for not feeling at risk N=504 N=115 N=619
I ensure a healthy lifestyle 164 32.5 28 24.3 192 31.0
I have no chronic illness to consider myself at risk for flu 150 29.8 24 20.9 174 28.1
Relying on natural defenses 135 26.8 16 13.9 151 24.4
I am too young to be at risk for flu 28 5.6 7 6.1 35 5.7
I try to avoid crowded environments 27 5.4 12 10.4 39 6.3
Other 0 0.0 28 24.3 28 4.5
How often do you receive a flu vaccine? N=1396 N=264 N=1660
Every year 769 55.1 49 18.6 818 49.3
Have not in the past - this is my first time 418 29.9 186 70.5 604 36.4
Every two years 101 7.2 8 3.0 109 6.6
Less than every two years 108 7.7 21 8.0 129 7.8
Main reason for missing previous vaccinations N=578 N=197 N=775
I didn’t feel I was at risk of getting flu 250 43.3 137 69.5 387 49.9
I was not encouraged to be vaccinated 187 32.4 5 2.5 192 24.8
I was afraid of side effects/contracting flu from the vaccine 79 13.7 8 4.1 87 11.2
I have a fear of injections/needle size 56 9.7 2 1.0 58 7.5
Other 6 1.0 45 22.8 51 6.6
What / who prompted you to receive your flu vaccine today? N=1394 N=264 N=1658
My own belief of the importance of flu vaccination 607 43.5 25 9.5 632 38.1
Family, friend or colleague 452 32.4 14 5.3 466 28.1
Physician/GP advice 210 15.1 201 76.1 411 24.8
Physician’s office assistant/practice nurse advice 63 4.5 1 0.4 64 3.9
Poster/communication in waiting room or pharmacy 39 2.8 2 0.8 41 2.5
Other 23 1.6 21 8.0 44 2.7
Which of the following would be most effective in reminding you 
of future flu vaccination?
N=1392 N=263 N=1655
Postcard/email/SMS alert sent by your nurse/physician’s 
assistant/GP clinic
521 37.4 57 21.7 578 34.9
Advice from your physician/GP 351 25.2 129 49.0 480 29.0
Advice/reminder from family or friend 170 12.2 10 3.8 180 10.9
Articles in the media 144 10.3 51 19.4 195 11.8
Other or none 206 14.8 16 6.1 222 13.4
Results were from a self-administered questionnaire. Percentages were calculated as 100 × (number in each category [n] ÷ 
the total number of responses available for each question [N]).
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Figure 1. Vaccinees’ satisfaction with Intanza® influenza vaccination and preferences for the following year. (A) Immediately 
after vaccination, vaccinees were asked “how satisfied are you with the vaccine you received today?” Possible responses were 
“very satisfied,” “satisfied,” “somewhat satisfied,” and “not satisfied.” Results were from the self-administered questionnaire 
completed just after vaccination. (B) Vaccinees responding “very satisfied,” “satisfied,” or “somewhat satisfied” to “how satisfied 
are you with the vaccine you received today?” were asked “what is the main reason for your satisfaction?” Possible responses 
were “the injection was minimally painful,” “I was reassured by the microneedle (short and thin needle),” “the administration 
process was quick,” and “other (specify reason...).” (C) Vaccinees were asked “for next year’s flu season, would you consider the 
following?” Possible responses were “to be vaccinated with the same vaccine as today,” “to be vaccinated with IM vaccine,” and 
“no vaccination.” The day of vaccination results were from the self-administered questionnaire completed immediately after 
vaccination, and the results for 7 to 10 days after vaccination were obtained by telephone survey. Percentages were calculated as 
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When asked immediately after vaccination 
about their vaccine preference for the following 
year, most vaccinees (96.7% in Australia, 87.0% 
in Argentina; 95.2% overall) answered “same as 
today” (Figure 1C). In Argentina, the response was 
the same (86.5%) when the vaccinees were asked 
a second time, 7 to 10 days after vaccination.
Vaccinees’ Opinions of the Most Effective 
Reminder to be Vaccinated 
In Australia, vaccinees reported that an email or 
text message would be the best way to remind 
them about future influenza vaccinations, 
followed by advice from a physician or GP 
(Table 2). In Argentina, these two methods were 
also cited most often as effective reminders, 
although “advice of a physician” was 
mentioned first and an “email or text message” 
as the second most effective reminder.
Prescriber Responses
Demographics
Thirty prescribers in Australia and 16 in 
Argentina answered survey questions about 
their perceptions of vaccination with Intanza 
9 μg. In Argentina, all prescribers were in the 
greater Buenos Aires area, and therefore in urban 
settings. In Australia, nearly all (29/30; 96.7%) 
practiced in an urban setting, and only one 
(3.3%) practiced in a peri-urban setting.
Prescriber Satisfaction with Intanza 9 μg
Most (76.7%) of the prescribers in Australia and 
all 16 (100%) in Argentina indicated that they 
were “satisfied” or “very satisfied” with the ID 
vaccine (Figure 2). Only two prescribers (4.3%, 
both in Australia) were “unsatisfied” with the ID 
vaccine. Most prescribers/vaccinators reported 
preferring ID over IM vaccination (70.0% [21/30] 
in Australia, 83.3% [10/12; 4 surveys unanswered] 
in Argentina; 73.8% [31/42] overall). 
DISCUSSION
This survey evaluated the acceptance in 
routine clinical practice of the first ID influenza 
vaccine, Intanza 9 μg, by both adult vaccinees 
and their prescribers. This study included a 
total of 1666 vaccinees and 46 prescribers in 
Australia and Argentina, who were surveyed 
during the 2010 southern hemisphere 
influenza season. The survey showed a high 
rate of acceptance of ID vaccination with 
Intanza 9 μg by both vaccinees and prescribers. 
Although randomized clinical studies in adults 
18 to 59 years have shown that Intanza 9 μg is 
non-inferior, has a similar safety profile, and 
a similar acceptance to Vaxigrip 15 μg,5,6 this 
was the first study to establish the acceptance 
of Intanza 9 μg in routine clinical practice.
Nearly all vaccinees (98% in both Australia 
and Argentina) considered Intanza 9 μg 
satisfactory or very satisfactory when asked 
immediately after vaccination. Also, when 
asked immediately after the vaccination, most 
vaccinees (97% in Australia, 87% in Argentina; 
95% overall) reported that they would choose 
to receive the same vaccination the following 
year. In the Argentinean study, the percentage 
did not change when the subjects were asked 
again 7 to 10 days after the vaccination (86.5% 
vs. 87% when first asked). This suggests that 
local and systemic reactions occurring within 
1 week of vaccination did not affect acceptability, 
although this study did not directly assess 
the impact or perceptions of local or systemic 
reactivity. These results agree with those of 
patient-reported outcomes obtained from phase 
3 clinical trials of Intanza, in which 96% of both 
adult and elderly subjects reported being satisfied 
with the injection system, and 96% to 97% 
considered the injection to be “very” to “totally” 
acceptable.9 Although other novel routes of 
administration exist or are being developed for 
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influenza vaccination,10-12 vaccinee satisfaction 
rates have not been reported for these. 
For the vaccinees who reported being satisfied 
with Intanza 9 μg, the most common reasons 
for satisfaction were that they considered the 
injection to be minimally painful and rapidly 
administered. Fear of needles appears not to have 
played an important role for most vaccinees, 
as only 14% in Australia and 5% in Argentina 
reported that they preferred ID vaccination 
with Intanza 9 μg because they were reassured 
by the microneedle. Likewise, fear of injections 
or needle size was reported by only 10% of 
vaccinees in Australia and 1% in Argentina as a 
reason for missing previous vaccinations. 
Professional opinion in favor of ID influenza 
vaccination with Intanza 9 μg was also high. 
Most (85%) of the prescribers surveyed indicated 
that they were satisfied or very satisfied with 
Intanza 9 μg.
Although acceptance of Intanza 9 μg 
by vaccinees was similar in Australia and 
Argentina, their attitudes toward seasonal 
influenza vaccination differed. Fewer vaccinees 
in Argentina (20%) than in Australia (55%) 
reported being vaccinated every year for 
seasonal influenza. The main reason for not 
being vaccinated was a lack of education about 
influenza, as shown by many responding that 
they were not vaccinated because they did 
not “feel at risk of contracting the flu,” and by 
relatively few being vaccinated because of their 
“own belief in the importance of vaccination.” 
Not feeling at risk for contracting influenza was 
also the most common reason reported for not 
being vaccinated in a study of patients with 
coronary heart disease in the United States,13 and 
a study in Poland and Sweden in the 2003/2004 
and 2004/2005 influenza seasons found that 
belief in being resistant to influenza was a main 
barrier to vaccination.14 In this context, advice 
from a doctor seems to be the most effective 
way of reminding people to be vaccinated in 
Argentina, whereas a specific reminder, such as 
an email or text message from the doctor’s office, 
seems to be the best reminder in Australia.
The results of this survey should be 
interpreted in light of certain aspects of the 
Figure 2. Prescribers’ satisfaction with the Intanza® vaccination. Prescribers were asked “how satisfied are you with the ID 
vaccine?” Possible responses were “very satisfied,” “satisfied,” “somewhat satisfied,” and “not satisfied.” Results were from a 
self-administered questionnaire. Percentages were calculated as 100 × (number in each category [n] ÷ the total number of 
responses available for each question [N]).
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study design. Firstly, only subjects electing to 
receive ID vaccination with Intanza 9 μg were 
included in the survey, so we could not directly 
compare the acceptability of IM and ID influenza 
vaccination. Including only those electing to 
receive ID vaccination might also have biased 
the results in favor of ID vaccination. However, 
the results were nearly the same as those found 
in phase 3 clinical trials that also assessed 
satisfaction with Intanza.9 Another consideration 
is that the survey was performed primarily in 
urban Australian and Argentinean clinics, and 
that different results might be obtained in 
other countries or more rural settings. However, 
satisfaction rates were similar in Argentina and 
Australia, suggesting that Intanza 9 μg is well 
accepted by adult vaccinees and prescribers, 
irrespective of the country.
In conclusion, this study showed that 
Intanza 9 μg was well accepted by adult 
vaccinees and vaccine prescribers in routine 
clinical practice. As such, Intanza 9 μg might 
have the additional benefit of increasing 
vaccination rates against seasonal influenza in 
adults by offering an alternative vaccine with 
a smaller needle and rapid administration. 
Finally, the study suggests that the most 
effective approaches for improving influenza 
vaccination coverage differ between countries. 
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